BackgroundExpression and activity of the fibroblast growth factor (FGF) 21 hormone-like protein are associated with development of several metabolic disorders. This study was designed to investigate whether serum FGF21 level was also associated with the metabolic syndrome-related cardiovascular disease, atherosclerosis, and its clinical features in a Chinese cohort.MethodsTwo-hundred-and-fifty-three subjects visiting the Cardiology Department (Sixth People's Hospital affiliated to Shanghai JiaoTong University) were examined by coronary arteriography (to diagnose coronary artery disease (CAD)) and hepatic ultrasonography (to diagnose non-alcoholic fatty liver disease (NAFLD)). Serum FGF21 level was measured by enzyme-linked immunosorbent assay and analyzed for correlation to subject and clinical characteristics. The independent factors of CAD were determined by multivariate logistic regression analysis.ResultsSubjects with NAFLD showed significantly higher serum FGF21 than those without NAFLD (388.0 pg/mL (253.0-655.4) vs. 273.3 pg/mL (164.9-383.7), P < 0.01). Subjects with CAD showed significantly higher serum FGF21, regardless of NAFLD diagnosis (P < 0.05). Serum FGF21 level significantly elevated with the increasing number of metabolic disorders (P for trend < 0.01). After adjustment of age, sex, and BMI, FGF21 was positively correlated with total cholesterol (P < 0.05) and triglyceride (P < 0.01). FGF21 was identified as an independent factor of CAD (odds ratio = 2.984, 95% confidence interval: 1.014-8.786, P < 0.05).ConclusionsIncreased level of serum FGF21 is associated with NAFLD, metabolic disorders and CAD.

Serum osteocalcin levels were inversely correlated with VFA in Chinese men.

No abstract

ObjectiveDecreased serum vitamin D level is a common observation in obese adults. Since no Chinese population-based study has yet evaluated the relationship between serum vitamin D levels and the accurate adiposity variables, this study investigated the association of serum vitamin D (assessed by 25-hydroxyvitamin D3 [25(OH)D3]) levels with precise body fat content and distribution in a cohort of Chinese men.MethodsSerum samples were collected from a total of 567 men with normal glucose tolerance (NGT) for assessment by electrochemiluminescence immunoassay to measure 25(OH)D3 levels. In addition, each participant underwent bioelectrical impedance analysis to quantify total body fat and magnetic resonance imaging to measure visceral fat area (VFA) and subcutaneous fat area (SFA).ResultsOverweight/obese (BMI ≥25 kg/m2) subjects had significantly lower serum 25(OH)D3 levels than non-overweight/non-obese (BMI <25 kg/m2) subjects (P  = 0.029). Greater fat mass and VFA were accompanied by a downward trend in serum 25(OH)D3 levels (P for trend <0.01). Among overweight/obese subjects, those with body fat percent ≥25% also had significantly lower serum 25(OH)D3 levels (P <0.05). Moreover, participants with VFA ≥80 cm2 had significantly lower serum 25(OH)D3 (P <0.05), regardless of BMI value. VFA was independently correlated with serum 25(OH)D3 levels (β  =  −0.023, P <0.001), even after adjustments for confounding factors. In addition, serum 25(OH)D3 levels were found to decrease by 0.26 ng/mL per 10 cm2 increment of VFA.ConclusionsSerum 25(OH)D3 levels were inversely associated with VFA in Chinese men with NGT.